SciELO - Scientific Electronic Library Online

vol.80 issue4Cognitive impairment due to adjuvant chemotherapy in breast cancer patients: A problem awaiting definition in PeruIs there really an “epidemic of depression”? author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista de Neuro-Psiquiatría

Print version ISSN 0034-8597


CASTRO-SUAREZ, Sheila; CAPARO-ZAMALLOA, César  and  MEZA-VEGA, María. Myasthenia gravis. Rev Neuropsiquiatr [online]. 2017, vol.80, n.4, pp.247-260. ISSN 0034-8597.

Myasthenia gravis (MG) is an autoimmune disease, characterized by fatigue and localized or generalized muscle weakness, with proximal predominance and fluctuating course; these symptoms stem from the post-synaptic blockade of neuromuscular transmission by antibodies against anti-acetylcholine antibodies and other post-synaptic membrane proteins. The incidence is 8 to 10 cases per million people, and the prevalence of 150 to 250 cases per million; however these figures vary in the different populations studied. The diagnosis of MG is based on the clinical manifestations and positive results of tests such as specific antibodies, neurophysiological tests or therapeutic interventions. The search for associated pathologies should be an important component of the evaluation. The treatment is based on three pillars: use of acetylcholinesterase inhibitors (pyridostigmine), immunotherapy (corticosteroids or immunosuppressants / immunomodulators) and surgical management (thymectomy).

Keywords : Myasthenia gravis; neuromuscular junction; thymoma.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License